NCT04192513View on ClinicalTrials.gov

Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo

PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions

Atopic Dermatitis

Interventions

DRUG

J. lividum

Investigational Product

Trial Locations (1)

Unknown

Instituto Dermatologico y Cirugia de Piel, Santo Domingo

Sponsors

Lead Sponsor

DermBiont, Inc.

All Listed Sponsors

lead

DermBiont, Inc.

INDUSTRY

NCT04192513 - Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo | Biotech Hunter | Biotech Hunter